Home/Pipeline/Noa‑001

Noa‑001

Inflammatory Bowel Disease

PreclinicalActive

Key Facts

Indication
Inflammatory Bowel Disease
Phase
Preclinical
Status
Active
Company

About Noa Therapeutics

A biotech startup using biased AhR modulation to create disease‑modifying small‑molecule therapies for chronic inflammation.

View full company profile

Other Inflammatory Bowel Disease Drugs

DrugCompanyPhase
DVI-001DivamicsPreclinical
DVI-002DivamicsPreclinical
Turq-101Turquoise BiotechnologiesPreclinical
GS-4875GileadPhase 2
Function-based Consortium for IBDPharmaBiomePre-clinical
Galapagos CollaborationScipher MedicineDiscovery/Pre-clinical
IBD SubclassificationBio-MeResearch
Anti-iRhom2 antibodiesSciRhomPre-clinical
IBD Multi-omics DatasetOvation.ioCommercial
InflectraEMSPhase 3
IW-601ImmuneWalk TherapeuticsPreclinical
TRWR‑IBDTaiwan Resonant Waves ResearchPreclinical